Form DEFA14A HAEMONETICS CORP
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant x | Filed by a Party other than the Registrant ☐ | ||||
Check the appropriate box: | |||||
☐ | Preliminary Proxy Statement | ||||
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
☐ | Definitive Proxy Statement | ||||
x | Definitive Additional Materials | ||||
☐ | Soliciting Material under §240.14a-12 | ||||
HAEMONETICS CORPORATION
(Name of Registrant as Specified in Its Charter)
| Payment of Filing Fee (Check the appropriate box): | |||||
| x | No fee required. | ||||
| ☐ | Fee paid previously with preliminary materials. | ||||
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | ||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Haemonetics (HAE) PT Raised to $85 at Mizuho
- Circles, Greyskies, and HCLTech Collaborate in TM Forum Catalyst Program to Accelerate AI-led Autonomous Network Operations
- LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
